GlassScriptPhysician profile
David K Berke
NPI 1356324966
$900.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $74.64 · 2021: $218.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $220.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $155.80 | 2019-2021 | |
| Amgen INC. | $105.42 | 2019 | |
| Boston Scientific Corporation | $95.93 | 2019-2021 | |
| Novo Nordisk INC | $65.78 | 2019-2021 | |
| Abbott Laboratories | $39.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2019 | |
| Merck Sharp & Dohme LLC | $33.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.26 | 2019 | |
| Genentech USA, INC. | $24.26 | 2019 | |
| Allergan, INC. | $23.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.63 | 2019 | |
| Lilly USA, LLC | $13.51 | 2020 | |
| Glaxosmithkline, LLC. | $12.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.